IDO1 and depressive disorder: These preclinical findings could warrant clinical investigations into the possibility of blocking 5-HT1A auto-receptors and/or IDO1 as a strategy to maintain the therapeutic effects of SSRI for the treatment of comorbid pain and depression in clinical settings.